Adicet Bio Inc (ACET) concluded trading on Wednesday at a closing price of $0.96, with 0.46 million shares of worth about $0.44 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -24.41% during that period and on January 08, 2025 the price saw a loss of about -2.24%. Currently the company’s common shares owned by public are about 82.40M shares, out of which, 66.22M shares are available for trading.
Stock saw a price change of -0.21% in past 5 days and over the past one month there was a price change of -8.57%. Year-to-date (YTD), ACET shares are showing a performance of -0.21% which decreased to -60.98% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.81 but also hit the highest price of $3.77 during that period. The average intraday trading volume for Adicet Bio Inc shares is 572.57K. The stock is currently trading 0.21% above its 20-day simple moving average (SMA20), while that difference is down -9.80% for SMA50 and it goes to -32.55% lower than SMA200.
Adicet Bio Inc (NASDAQ: ACET) currently have 82.40M outstanding shares and institutions hold larger chunk of about 51.43% of that.
The stock has a current market capitalization of $79.11M and its 3Y-monthly beta is at 1.87. It has posted earnings per share of -$1.71 in the same period. It has Quick Ratio of 10.64 while making debt-to-equity ratio of 0.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ACET, volatility over the week remained 10.02% while standing at 8.51% over the month.
Stock’s fiscal year EPS is expected to rise by 51.96% while it is estimated to decrease by -2.83% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Guggenheim on September 30, 2024 offering a Buy rating for the stock and assigned a target price of $7 to it. Stock get a Neutral rating from JP Morgan on June 01, 2023.
